Understanding how blood vessel cells contribute to blood clots in certain blood cancers
Official title: Engineered microsystems to assess endothelial contribution to myeloproliferative neoplasm thrombosis
Funded at University of Minnesota · NIH-10895325 · Data updated 2026-11-12
This study is looking at how certain cells in your blood vessels might contribute to blood clots in people with myeloproliferative neoplasms (MPNs), especially those with a specific mutation, and it aims to understand how current medications can help, with the possibility of you providing blood samples to assist in this research.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Minnesota NIH-funded |
| Lab location | 1 site (Minneapolis, United States) |
| Project start | August 1, 2022 |
| Project end | July 31, 2027 |
| Funding year | 2024 |
| Award (this year) | $171,180 |
| NIH project number | 5K08HL159289-03 |
| Project ID | NIH-10895325 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with myeloproliferative neoplasms, particularly those with the JAK2V617F+ mutation.
✕Less likely to help
Patients without myeloproliferative neoplasms or those who do not have the JAK2V617F+ mutation may not benefit from this research.
What this research studies
This research investigates the role of endothelial cells, which line blood vessels, in the development of thrombosis (blood clots) in patients with myeloproliferative neoplasms (MPNs). The study focuses on how a specific mutation, JAK2V617F+, affects these cells and their interaction with blood components, potentially leading to increased clotting risks. By using engineered microsystems, researchers aim to better understand the mechanisms behind this process and evaluate the effects of existing medications on these cells. Patients may be involved in providing blood samples to help characterize these interactions.
Why it matters
Potential benefit: If successful, this research could lead to improved treatments for preventing thrombosis in patients with myeloproliferative neoplasms.
How similar studies have gone: Previous research has shown promising results in understanding the role of endothelial cells in thrombosis, suggesting that this approach may yield valuable insights.
Where this research is happening
-
University of Minnesota
Minneapolis, United States Active
Researchers
- Principal investigator: Beckman, Joan Denise — University of Minnesota
- Study coordinator: Beckman, Joan Denise
Related research
Other NIH-funded projects on the same topics.
-
Complement and clotting in JAK2V617F myeloproliferative neoplasms
A short, patient-friendly study will look at how a specific mutation in blood cells may trigger the body’s complement system to cause clots in people with myeloproliferative neoplasms.
-
Endothelial contribution to blood-clotting in myeloproliferative neoplasms
This project explores how the lining of blood vessels may drive dangerous clots in people with myeloproliferative neoplasms (MPNs).
-
Hypoxia-inducible factors and neutrophil diversity in blood clotting in myeloproliferative neoplasms
A physician-scientist is training over five years to uncover how low-oxygen signals and diverse neutrophils drive dangerous clots in people with myeloproliferative neoplasms, with the goal of finding new treatment targets.
-
Understanding blood clotting mechanisms in certain blood cancers
This study is looking into how blood clots form in people with myeloproliferative neoplasms (a type of blood cancer) to find new ways to help prevent serious complications, and it’s designed for patients who want to learn more about their condition and potential treatments.
-
Inherited genetic risks shaping myeloid cancer initiation
A research project at Boston Children’s Hospital is exploring how inherited genetic differences may push blood stem cells toward the start of myeloproliferative neoplasms, with potential implications for earlier detection and prevention.
-
Understanding why some myeloproliferative neoplasm patients resist interferon therapy
Researchers are studying why interferon-alpha works for some blood cancer patients but not others, by looking closely at stem cells from CALR-mutated myeloproliferative neoplasms.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.